Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies
• Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must...
Ausführliche Beschreibung
Autor*in: |
Manafikhi, Husseen [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2017 |
---|
Schlagwörter: |
---|
Umfang: |
8 |
---|
Übergeordnetes Werk: |
Enthalten in: miR-214 in stroma cells and tumor progression - Dettori, D. ELSEVIER, 2016, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:110 ; year:2017 ; pages:35-42 ; extent:8 |
Links: |
---|
DOI / URN: |
10.1016/j.critrevonc.2016.12.007 |
---|
Katalog-ID: |
ELV040542475 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV040542475 | ||
003 | DE-627 | ||
005 | 20230624074151.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180603s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.critrevonc.2016.12.007 |2 doi | |
028 | 5 | 2 | |a GBVA2017017000008.pica |
035 | |a (DE-627)ELV040542475 | ||
035 | |a (ELSEVIER)S1040-8428(16)30369-9 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 610 | |
082 | 0 | 4 | |a 610 |q DE-600 |
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.52 |2 bkl | ||
100 | 1 | |a Manafikhi, Husseen |e verfasserin |4 aut | |
245 | 1 | 0 | |a Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies |
264 | 1 | |c 2017 | |
300 | |a 8 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a • Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status. | ||
650 | 7 | |a Total Antioxidant Capacity |2 Elsevier | |
650 | 7 | |a Beta-thalassemia |2 Elsevier | |
650 | 7 | |a Bilirubin |2 Elsevier | |
650 | 7 | |a Uric acid |2 Elsevier | |
650 | 7 | |a Meta-analysis |2 Elsevier | |
700 | 1 | |a Drummen, Gregor |4 oth | |
700 | 1 | |a Palmery, Maura |4 oth | |
700 | 1 | |a Peluso, Ilaria |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Dettori, D. ELSEVIER |t miR-214 in stroma cells and tumor progression |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019637179 |
773 | 1 | 8 | |g volume:110 |g year:2017 |g pages:35-42 |g extent:8 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.critrevonc.2016.12.007 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2016 | ||
912 | |a GBV_ILN_2048 | ||
936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
951 | |a AR | ||
952 | |d 110 |j 2017 |h 35-42 |g 8 | ||
953 | |2 045F |a 610 |
author_variant |
h m hm |
---|---|
matchkey_str |
manafikhihusseendrummengregorpalmerymaur:2017----:oaatoiataaiyneahlseiaytmtceiwnmtaa |
hierarchy_sort_str |
2017 |
bklnumber |
44.52 |
publishDate |
2017 |
allfields |
10.1016/j.critrevonc.2016.12.007 doi GBVA2017017000008.pica (DE-627)ELV040542475 (ELSEVIER)S1040-8428(16)30369-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Manafikhi, Husseen verfasserin aut Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies 2017 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status. Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis Elsevier Drummen, Gregor oth Palmery, Maura oth Peluso, Ilaria oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:110 year:2017 pages:35-42 extent:8 https://doi.org/10.1016/j.critrevonc.2016.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 110 2017 35-42 8 045F 610 |
spelling |
10.1016/j.critrevonc.2016.12.007 doi GBVA2017017000008.pica (DE-627)ELV040542475 (ELSEVIER)S1040-8428(16)30369-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Manafikhi, Husseen verfasserin aut Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies 2017 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status. Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis Elsevier Drummen, Gregor oth Palmery, Maura oth Peluso, Ilaria oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:110 year:2017 pages:35-42 extent:8 https://doi.org/10.1016/j.critrevonc.2016.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 110 2017 35-42 8 045F 610 |
allfields_unstemmed |
10.1016/j.critrevonc.2016.12.007 doi GBVA2017017000008.pica (DE-627)ELV040542475 (ELSEVIER)S1040-8428(16)30369-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Manafikhi, Husseen verfasserin aut Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies 2017 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status. Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis Elsevier Drummen, Gregor oth Palmery, Maura oth Peluso, Ilaria oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:110 year:2017 pages:35-42 extent:8 https://doi.org/10.1016/j.critrevonc.2016.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 110 2017 35-42 8 045F 610 |
allfieldsGer |
10.1016/j.critrevonc.2016.12.007 doi GBVA2017017000008.pica (DE-627)ELV040542475 (ELSEVIER)S1040-8428(16)30369-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Manafikhi, Husseen verfasserin aut Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies 2017 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status. Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis Elsevier Drummen, Gregor oth Palmery, Maura oth Peluso, Ilaria oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:110 year:2017 pages:35-42 extent:8 https://doi.org/10.1016/j.critrevonc.2016.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 110 2017 35-42 8 045F 610 |
allfieldsSound |
10.1016/j.critrevonc.2016.12.007 doi GBVA2017017000008.pica (DE-627)ELV040542475 (ELSEVIER)S1040-8428(16)30369-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Manafikhi, Husseen verfasserin aut Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies 2017 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status. Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis Elsevier Drummen, Gregor oth Palmery, Maura oth Peluso, Ilaria oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:110 year:2017 pages:35-42 extent:8 https://doi.org/10.1016/j.critrevonc.2016.12.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 110 2017 35-42 8 045F 610 |
language |
English |
source |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:110 year:2017 pages:35-42 extent:8 |
sourceStr |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:110 year:2017 pages:35-42 extent:8 |
format_phy_str_mv |
Article |
bklname |
Therapie |
institution |
findex.gbv.de |
topic_facet |
Total Antioxidant Capacity Beta-thalassemia Bilirubin Uric acid Meta-analysis |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
miR-214 in stroma cells and tumor progression |
authorswithroles_txt_mv |
Manafikhi, Husseen @@aut@@ Drummen, Gregor @@oth@@ Palmery, Maura @@oth@@ Peluso, Ilaria @@oth@@ |
publishDateDaySort_date |
2017-01-01T00:00:00Z |
hierarchy_top_id |
ELV019637179 |
dewey-sort |
3610 |
id |
ELV040542475 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040542475</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624074151.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2016.12.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017017000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040542475</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(16)30369-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Manafikhi, Husseen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Total Antioxidant Capacity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Beta-thalassemia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bilirubin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Uric acid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Meta-analysis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drummen, Gregor</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palmery, Maura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peluso, Ilaria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:110</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:35-42</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2016.12.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">110</subfield><subfield code="j">2017</subfield><subfield code="h">35-42</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
author |
Manafikhi, Husseen |
spellingShingle |
Manafikhi, Husseen ddc 610 bkl 44.52 Elsevier Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies |
authorStr |
Manafikhi, Husseen |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019637179 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 610 DE-600 610 VZ 44.52 bkl Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis Elsevier |
topic |
ddc 610 bkl 44.52 Elsevier Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis |
topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis |
topic_browse |
ddc 610 bkl 44.52 Elsevier Total Antioxidant Capacity Elsevier Beta-thalassemia Elsevier Bilirubin Elsevier Uric acid Elsevier Meta-analysis |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
g d gd m p mp i p ip |
hierarchy_parent_title |
miR-214 in stroma cells and tumor progression |
hierarchy_parent_id |
ELV019637179 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
miR-214 in stroma cells and tumor progression |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV019637179 |
title |
Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies |
ctrlnum |
(DE-627)ELV040542475 (ELSEVIER)S1040-8428(16)30369-9 |
title_full |
Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies |
author_sort |
Manafikhi, Husseen |
journal |
miR-214 in stroma cells and tumor progression |
journalStr |
miR-214 in stroma cells and tumor progression |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2017 |
contenttype_str_mv |
zzz |
container_start_page |
35 |
author_browse |
Manafikhi, Husseen |
container_volume |
110 |
physical |
8 |
class |
610 610 DE-600 610 VZ 44.52 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Manafikhi, Husseen |
doi_str_mv |
10.1016/j.critrevonc.2016.12.007 |
dewey-full |
610 |
title_sort |
total antioxidant capacity in beta-thalassemia: a systematic review and meta-analysis of case-control studies |
title_auth |
Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies |
abstract |
• Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status. |
abstractGer |
• Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status. |
abstract_unstemmed |
• Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 |
title_short |
Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies |
url |
https://doi.org/10.1016/j.critrevonc.2016.12.007 |
remote_bool |
true |
author2 |
Drummen, Gregor Palmery, Maura Peluso, Ilaria |
author2Str |
Drummen, Gregor Palmery, Maura Peluso, Ilaria |
ppnlink |
ELV019637179 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth |
doi_str |
10.1016/j.critrevonc.2016.12.007 |
up_date |
2024-07-06T17:44:54.115Z |
_version_ |
1803852598860578816 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040542475</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624074151.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2016.12.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017017000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040542475</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(16)30369-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Manafikhi, Husseen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Total Antioxidant Capacity (TAC) is decreased in thalassemics versus healthy subjects. • Similar decreased TAC levels were found in beta-thalassemia major and trait. • No relationship between TAC and disease severity could be established. • The possible interference of uric acid and bilirubin must be taken into account. • Uric acid-independent TAC might be the better approach to evaluate antioxidant status.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Total Antioxidant Capacity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Beta-thalassemia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bilirubin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Uric acid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Meta-analysis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drummen, Gregor</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palmery, Maura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peluso, Ilaria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:110</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:35-42</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2016.12.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">110</subfield><subfield code="j">2017</subfield><subfield code="h">35-42</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
score |
7.400962 |